Elvitegravir

From Self-sufficiency
Jump to: navigation, search
Elvitegravir
File:Elvitegravir.png
File:Elvitegravir3D.PNG
Systematic (IUPAC) name
6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
Identifiers
CAS Number 697761-98-1
ATC code none
PubChem CID 5277135
Chemical data
Formula C23H23ClFNO5
Molar mass 447.883 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Elvitegravir (EVG) is an investigational new drug for the treatment of HIV infection. It acts as an integrase inhibitor. It is undergoing Phase III clinical trial[1] conducted by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2005.[2][3][4]

According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.[5]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
fr:Elvitégravir pt:Elvitegravir
  1. Gilead Press Release Phase III Clinical Trial of Elvitegravir July 22, 2008
  2. Gilead Press Release Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor March 22, 2005
  3. Shimura K, Kodama E, Sakagami Y; et al. (2007). "Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137)". J Virol. 82 (2): 764. doi:10.1128/JVI.01534-07. PMC 2224569Freely accessible. PMID 17977962. 
  4. Stellbrink HJ (2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline ?". Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730. 
  5. Thaczuk, Derek and Carter, Micheal. ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents Aidsmap.com. 19 Sept. 2007.